PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Bifido achieved revenue growth and an operating profit turnaround after Whanin Pharmaceutical became its largest shareholder in 2024, but quarterly net income volatility and early-stage drug pipeline risk remain.
2025 consolidated revenue reached KRW 19.68 billion with operating profit of KRW 1.40 billion, turning positive from a KRW 4.49 billion operating loss in 2024.
Owner net income over the trailing four quarters (2025Q3–2026Q2) showed sharp swings, spiking notably in 2026Q1 (KRW 2.67 billion).
In August 2024, Whanin Pharmaceutical acquired a 30% stake from Amicogen for KRW 15 billion, becoming the largest shareholder.
The company signed a deal to sell its Microbiome Center building in Daechi-dong, Seoul for KRW 25.4 billion, with the transfer completed after final payment in August 2026.
The company has completed an IND application for Phase 1 trials of its microbiome-based rheumatoid arthritis candidate 'BFD1R01', among other pipeline programs.
Founded in 1999, Bifido became the first microbiome company to list on KOSDAQ via the technology special listing track in 2018.
Its core business is manufacturing and selling probiotic raw materials and finished products based on Bifidobacterium strains (BGN4, BORI), operated alongside its own brand and domestic/overseas ODM services.
Its proprietary strains were the first in Korea and the sixth globally to receive both New Dietary Ingredient (NDI) and Generally Recognized as Safe (GRAS) certification from the U.S. FDA.
Unlike most domestic health-supplement makers that focus on Lactobacillus strains, Bifido's emphasis on Bifidobacterium is considered a point of differentiation. Overseas sales account for a meaningful share of revenue, with export markets expanded to China, Saudi Arabia, Vietnam, and Turkey, among others.
In August 2024, Whanin Pharmaceutical acquired a 30% stake from Amicogen to become the largest shareholder, and Whanin's second-generation owner, CEO Lee Won-beom, now also serves as Bifido's CEO. Whanin has stated plans to expand synergies through its health-supplement distribution subsidiary, Adsyou.
As part of business diversification, Bifido is also developing microbiome-based drug candidates including a rheumatoid arthritis treatment and an idiopathic pulmonary fibrosis treatment.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩6.2B | ₩1.3B | 21.6% |
| 2025Q3 | ₩3.7B | -₩400M | −10.1% |
| 2025Q4 | ₩4.8B | ₩400M | 7.4% |
| 2026Q1 | ₩2.5B | -₩600M | −23.9% |
| 2026Q2 | ₩3.6B | -₩400M | −11.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩14.6B | ₩1.3B | ₩1.5B | 8.7% | 2.9% | 4.7% |
| 2023 | ₩18.6B | -₩300M | ₩1.1B | −1.8% | 2.1% | 38.7% |
| 2024 | ₩12.4B | -₩4.5B | -₩5.4B | −36.4% | −11.6% | 31.1% |
| 2025 | ₩19.7B | ₩1.4B | -₩200M | 7.1% | −0.4% | 33.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
2025 consolidated revenue was KRW 19.68 billion, up 59.3% from KRW 12.35 billion in 2024, while operating profit turned to KRW 1.40 billion from an operating loss of KRW 4.49 billion the prior year.
Owner net income improved to a loss of KRW 192.7 million, a sharp narrowing from the KRW 5.40 billion loss recorded in 2024. The large 2024 operating loss reflected rising drug-development costs combined with softer sales, while 2025's improvement was driven by growth in domestic accounts and expanded overseas sales.
Looking at the trailing four quarters (2025Q3–2026Q2), results show pronounced volatility.
Revenue was KRW 3.71 billion with an operating loss of KRW 375 million in 2025Q3, followed by a seasonal recovery to KRW 4.83 billion revenue and KRW 360 million operating profit in 2025Q4; but in 2026Q1 revenue fell to KRW 2.50 billion with an operating loss of KRW 597 million, even as owner net income jumped to KRW 2.67 billion, suggesting a significant non-operating item.
In 2026Q2, revenue was KRW 3.60 billion with an operating loss of KRW 410 million and net income of KRW 318 million, continuing the gap between operating results and net income. Annual operating margin moved from 8.7% in 2022 to -1.8% in 2023 and -36.4% in 2024, before recovering to 7.1% in 2025.
The debt ratio rose from 4.7% in 2022 to the 30%-plus range in 2023–2024 and stood at 33.5% in 2025, indicating manageable financial leverage.
The global probiotics market is reported to have grown from roughly KRW 46 trillion in 2014 to about KRW 80 trillion recently. Korea's health-supplement market is seeing increasing consumer concentration around leading brands, which highlights the competitive edge of companies with proven strains and clinical data.
Domestic probiotics players include HPO, Cell Biotech, Chong Kun Dang's subsidiary Chong Kun Dang Healthcare, and Il-Dong Pharmaceutical's subsidiary Il-Dong Bioscience, with HPO cited as a standout example of steady annual revenue growth.
Bifido's market position differs in that its core strain is Bifidobacterium rather than Lactobacillus, though its overall revenue scale remains relatively small compared to peers.
The microbiome-based therapeutics market remains in an early commercialization stage globally, with multiple domestic and international companies conducting clinical trials whose outcomes will need to be monitored over an extended period.
Since joining the Whanin group, Bifido has gained access to a pharmaceutical company's distribution network and financial resources, which may somewhat improve its relative competitive standing.
The company has stated plans to sequentially register individually-approved functional ingredients—covering bowel function, bad-breath relief, hypersensitive-skin immune improvement, urinary health, and cognitive improvement—by 2026, and is also pursuing regulatory approval for body-fat reduction and hypersensitive-skin immune functionality claims.
On the drug pipeline side, the company has completed an IND application for Phase 1 trials of its rheumatoid arthritis candidate 'BFD1R01', with subsequent approval and trial initiation to watch going forward.
The company signed an agreement to sell its Microbiome Center building in Daechi-dong for KRW 25.4 billion, with the transfer completed following final payment in August 2026. Proceeds are reported to be earmarked for balance-sheet improvement and capacity (CAPA) investment.
Whanin Pharmaceutical has also outlined plans to expand synergies with its health-supplement subsidiary, Adsyou. Overseas, promotional expansion through new partnerships, including in Vietnam, is reportedly underway.
How much these factors translate into actual revenue and profit will need to be confirmed through upcoming quarterly disclosures.
The current share price trades at a level below the company's net asset value per share, which can be read as reflecting years of weak performance and uncertainty stemming from the listing-eligibility review process.
On the earnings side, the trajectory has improved—from a large loss in 2024 to a profit turnaround in 2025, and to positive net income on a trailing-four-quarter basis.
However, given the wide swings in quarterly net income and the apparent influence of non-operating items, the sustainability of earnings quality warrants further confirmation in coming quarters. No recent dividend payment history was identified, limiting the shareholder-return metrics available for reference.
Valuation multiples reflect different phases—one from the earlier period of weak performance and another from the recent profit turnaround—so they are better assessed alongside future earnings trends rather than through simple comparison alone.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
2025 revenue grew 59.3% year over year and operating profit turned positive for the first time in three years. Both growing domestic accounts and expanding overseas sales contributed, broadening the revenue base. Net income has also been positive on a trailing four-quarter basis, indicating an improving trajectory.
Since Whanin became the largest shareholder in 2024, management normalization has proceeded alongside asset sales that boosted liquidity. Selling the Daechi-dong building for KRW 25.4 billion, exceeding the original acquisition investment, can be read as an expansion of financial flexibility.
Business linkage with health-supplement distribution subsidiary Adsyou could also contribute to expanding sales channels going forward.
Bifido holds Bifidobacterium strains that were the first in Korea and sixth globally to receive FDA NDI and GRAS certification, giving it relatively distinct raw-material competitiveness.
Building on these strains, the company is developing microbiome-based drug candidates including a rheumatoid arthritis treatment, having progressed to an IND application for Phase 1 trials.
Should the drug pipeline advance further, it could add a valuation dimension distinct from the existing health-supplement business.
Revenue over the trailing four quarters fluctuated between roughly KRW 2.5 billion and KRW 4.8 billion, and operating results swung between profit and loss each quarter. 2026Q1 posted an operating loss alongside a sharp jump in net income, while 2026Q2 reverted to an operating loss with lower net income.
Because the revenue base remains relatively small, seasonality and one-off items tend to produce pronounced swings in reported results.
In 2026Q1, owner net income rose sharply despite an operating loss, suggesting a significant contribution from non-operating items. In such a structure, it is difficult to gauge the pace of underlying operating improvement from net income alone.
It will be important to continue checking whether operating profit and net income move in the same direction in coming quarters.
Microbiome drug candidates such as the rheumatoid arthritis treatment remain at the Phase 1 IND application stage, meaning commercialization could take a long time. Clinical development entails substantial costs, and the large 2024 operating loss was partly attributed to rising drug-development expenses. The success or failure of the drug pipeline remains difficult to predict at this stage.
Quarterly revenue has swung widely, from roughly KRW 2.5 billion to KRW 6.2 billion, suggesting reliance on specific accounts or export volumes can heavily influence results. The revenue base does not yet appear to be firmly diversified.
The debt ratio rose from 4.7% in 2022 to the 30%-plus range in 2023–2025, and the company previously became subject to a listing-eligibility review following an embezzlement incident, warranting continued scrutiny of internal controls.
Liquidity was raised through an asset sale, but the efficiency of future capital deployment also bears watching.
Registration of individually-approved functional ingredients and related regulatory approvals remain pending, with review timelines and outcomes not yet finalized, so delays or rejections beyond expectations cannot be ruled out. The drug pipeline also carries the inherent risk of failure at any clinical stage.
The 2026Q3 earnings disclosure will be worth checking to see whether revenue and operating profit remain positive and whether net income volatility eases.
This is a point to check progress on regulatory approval and registration of individually-approved functional ingredients such as body-fat reduction and hypersensitive-skin immune improvement.
Whether Phase 1 trial approval is granted and when trials begin for the rheumatoid arthritis candidate 'BFD1R01' should be confirmed.
It will be important to confirm how the KRW 25.4 billion proceeds from the Microbiome Center building sale are actually deployed toward CAPA investment and balance-sheet improvement.
The full-year 2026 (including Q4) earnings release will be worth reviewing to see whether annual revenue sets a new record and whether the profit trend is sustained.
Bifido has shown a clear improvement trend, achieving revenue growth and an operating profit turnaround following the 2024 change in largest shareholder to Whanin Pharmaceutical.
However, quarterly net income has varied widely, and the recent pattern of a net income surge alongside an operating loss highlights a notable non-operating influence, meaning the sustainability of earnings quality requires further confirmation.
Liquidity gained from the Microbiome Center building sale and distribution/financial support from the Whanin group can be viewed as factors expanding financial flexibility.
At the same time, the drug pipeline, including the rheumatoid arthritis candidate, remains at a pre-Phase 1 stage, leaving considerable time and uncertainty before any commercialization.
The pace of regulatory processes, such as individually-approved functional ingredient registration and related approvals, is another variable that could affect results.
Overall, early signs of earnings improvement are unfolding alongside structural business changes, warranting continued attention to upcoming quarterly results and the realization of key events.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.